Clinical-stage biopharmaceutical company IO Biotech, a developer of novel, immune modulating anti-cancer therapies based on its proprietary T-win technology, revealed on Wednesday that it has initiated the Phase 2 portion of a global, open-label, randomised clinical trial studying the investigational candidate IO102 in combination with KEYTRUDA (pembrolizumab) for the treatment of first-line patients with metastatic non-small cell lung cancer (NSCLC).
IO Biotech said Phase 2 of the IO102-012/KN-764 trial follows the successful completion of the safety portion of the trial of IO102. The clinical trial is expected to accrue 96 patients across more than 20 sites in the US and Europe.
This trial is part of a collaborative agreement with Merck & Co Inc, Kenilworth NJ USA (known as MSD outside the US and Canada). IO Biotech will sponsor the clinical trial, while MSD will supply the trial with KEYTRUDA. The company added that the rights to the study results will be shared, and IO Biotech has retained global commercial rights to IO102.
The company stated that IO102 is its lead candidate and is an Indoleamine 2,3-dioxygenase (IDO) derived immune modulating therapy with a dual mode of action - killing both cancer cells and immune-suppressive cells. IDO-derived immune modulating therapies previously demonstrated both a favourable safety profile and promising anti-tumour activity in its first human clinical trial of heavily pre-treated patients with NSCLC.
AstraZeneca launches Phase III THARROS trial for BREZTRI in COPD to assess cardiopulmonary outcomes
Merck finalises acquisition of Harpoon Therapeutics Inc
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
Nuvalent's NVL-520 receives FDA breakthrough therapy designation
Dassault Systèmes enhances patient care with virtual twin experience at Paris hospital
Pulmonx initiates CONVERT II trial for AeriSeal System in COPD treatment
Priority Review of Dupixent underway by FDA for COPD treatment
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
AstraZeneca reports positive resultsfor Tagrisso in Stage III lung cancer trial
AstraZeneca announces US acceptance of BLA for datopotamab deruxtecan to treat lung cancer
Erasca agrees clinical trial deal with Novartis to study naporafenib in combination with trametinib
FDA accepts Bristol Myers Squibb's Augtyro application for Priority Review